Skip to main content

Table 1 Characteristics of groups 1 and 2 at acromegaly diagnosis and at baseline

From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

  

All patients

Group 1 PEGV

Group 2 PEGV?+?SSA

A

Patients – n (%)

62 a

35 (56.4)

27 (43.6)

T

Males

21 (33.9)

11 (31)

10 (37)

D

Age at diagnosis (y) - median (range)

33 (18–72)

39 (21–72)

31 (18–70)

I

Patients with macroadenomas – n (%)

50 (83%)

28 (80)

22 (81.5)

A

Comorbidities - n (%)

   

G

Hypertension

25 (40.3)

15 (42.8)

10 (37)

N

Diabetes

22 (35.5)

15 (42.8)

7 (25.9)

O

Cardiomyopathy

23 (37.1)

12 (34.2)

11 (40.7)

S

Sleep apnea

24 (38.7)

6 (17.1)

18 (66.6)*

I

Vertebral fractures

16 (25.8)

12 (34.2)

4 (14.8)

S

Goiter

23 (27.1)

12 (34.2)

11 (40.7)

Colon cancer

3 (4.8)

1 (2.8)

2 (7.4)

Hypopituitarism – n (%)

27 (43.5)

13 (37.1)

14 (51.8)

ACTH deficiency

4 (6.5)

2 (5.7)

2 (7.4)

LH/FSH deficiency

25 (40.3)

13 (37.1)

12 (44.4)

TSH deficiency

7 (11.3)

5 (14.2)

2 (7.4)

Vasopressin deficiency

0 (0)

0 (0)

0 (0)

Hyperprolactinemia – n (%)

12 (19.3)

6 (17.1)

6 (22.2)

GH nadir - μg/L b

   

Median (range)

10.25 (2.2-100)

9.4 (2.2-63.1)

17.1 (3.3-100)*

Mean (±SD)

22.2 (±23)

16.9 (±17.3)

29 (±27.6)*

IGF-I levels

   

μg/L, Median (range)

715 (315–1587)

670 (315–1210)

899 (425–1587)*

SDS (range)

9.9 (2.9-22.2)

8.8 (2.9-22.2)

10.9 (3.6-21.7)*

ng/ml, Mean (±SD)

804 (±246)

723 (±216)

906 (±254)

A

BMI (kg/m2) – median (range)

28.7 (19.1-42)

27 (20–42)

30 (19.1-37.8)

T

Estimated disease duration (y) – median (range)

5 (2–20)

5 (2–20)

5 (2–20)

B

Previous treatments – n (%)

   

A

Surgery – n (%)

59 (95.2)

33 (94.2)

26 (96.3)

S

Residual adenoma

39 (62.9)

17 (51.5)

22 (84.6)*

E

Somatostatin analogs - n (%)

62 (100)

35 (100)

27 (100)

L

Duration of treatment (y) – median (range)

4 (2–17)

4 (2–16)

4 (2–17)

I

Radiotherapy - n (%)

16 (25.8)

7 (20)

9 (33)

N

Dopamine agonists - n (%)

13 (20.9)

7 (20)

6 (22)

E c

GH levels - μg/L d

   

Median (range)

11 (0.8-77)

8.4 (0.8-77)

18 (3.8-74.0)*

Mean (±SD)

21.4 (±21)

17.2 (±19.7)

30.9 (±22.5)*

IGF-I levels

   

μg/L , Median (range)

621.5 (431–1621)

632 (431–1621)

592 (455–929)#

SDS (range)

6.9 (2.7-19.5)

6.9 (2.7-19.1)

5.9 (3.4-16.5)#

μg/L , Mean (±SD)

673(±224)

736 (±258)

661 (±162)#

Δ IGF-Ie

   

μg/L , Median (range)

132 (−411-872)

57 (−411-692)

205 (−115-872)*

SDS (range)

2 (−5.8-13.4)

0.9 (−5.8-11.2)

3.1 (−1.7-13.4)*

 

μg/L , Mean (±SD)

131 (±266)

38 (±250)

251 (±241)*

  1. The results are shown as median (range) or number (percent), unless otherwise specified. Abbreviations: BMI body mass index, PEGV pegvisomant, SSA somatostatin analogs, SDS standard deviation score.
  2. Systeme Internationale conversion factors: GH (μg/L), X 3.0?=?mUI/L; IGF-I (μg/L), X 0.131?=?nmol/L.
  3. a Nineteen were analyzed in the Acrostudy Italy;
  4. b GH nadir?=?value observed after oral glucose tolerance test (OGTT);
  5. c Baseline: End of SSA monotherapy, immediately before PEGV was started.
  6. d Expressed as averages of GH day curve (4 points over 2 hours).
  7. e Level observed at diagnosis minus level observed at baseline.
  8. * p?<?0.05 vs. Group 1 (Mann–Whitney U test); # p?<?0.05 vs. diagnosis (Wilcoxon rank sum test).
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us